Insulet Corp. (PODD) Depreciation & Amortization
The d&a for Insulet Corp. (PODD) is $113.10 Million with a year-over-year change of +39.98%. Depreciation and Amortization (D&A) is a non-cash expense that allocates the cost of tangible and intangible assets over their useful lives.
PODD D&A Chart
Reported annual fiscal-period values; no daily interpolation.
Current D&A
$113.10M
$113.10 Million
Year-over-Year Change
+39.98%
vs. $80.80M prior year
Historical Data
24
Years of data available
Annual D&A History
| Year | D&A | YoY Change | % Change |
|---|---|---|---|
| 2025 | $113.10M | +$32.30M | +39.98% |
| 2024 | $80.80M | +$8.00M | +10.99% |
| 2023 | $72.80M | +$9.60M | +15.19% |
| 2022 | $63.20M | +$5.80M | +10.10% |
| 2021 | $57.40M | +$2.00M | +3.61% |
| 2020 | $55.40M | +$27.50M | +98.57% |
| 2019 | $27.90M | +$12.30M | +78.85% |
| 2018 | $15.60M | +$1.70M | +12.23% |
| 2017 | $13.90M | +$67,000 | +0.48% |
| 2016 | $13.83M | $-2.00M | -12.66% |
| 2015 | $15.84M | +$3.62M | +29.58% |
| 2014 | $12.22M | +$417,000 | +3.53% |
| 2013 | $11.81M | +$776,000 | +7.04% |
| 2012 | $11.03M | +$2.53M | +29.72% |
| 2011 | $8.50M | +$3.43M | +67.48% |
| 2010 | $5.08M | $-145,000 | -2.78% |
| 2009 | $5.22M | $-1.15M | -18.09% |
| 2008 | $6.38M | +$1.46M | +29.57% |
| 2007 | $4.92M | +$2.28M | +86.36% |
| 2006 | $2.64M | +$1.40M | +113.59% |
| 2005 | $1.24M | +$913,000 | +282.66% |
| 2004 | $323,000 | +$323,000 | — |
| 2003 | $0 | +$0 | — |
| 2002 | $0 | — | — |
Related Metrics
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy